Drug Trial Radar · NCT03734016
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
652
Actual
Start
Nov 1, 2018
Primary completion
Aug 8, 2022
Study completion Feb 28, 2024
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Nov 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
ZanubrutinibDrug
160 mg orally twice daily
IbrutinibDrug
Ibrutinib 420 mg orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) Assessed by the InvestigatorTime frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
- ORR Assessed by the Independent Review Committee (IRC)Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Locations
115 sites in 15 countries. Site status is shown where the registry gives one.
Carti Cancer Center
Little Rock, Arkansas
David Geffen School of Medicine At UCLA
Los Angeles, California
Rocky Mountain Cancer Centers Boulder
Boulder, Colorado
Scri Florida Cancer Specialists South
Fort Myers, Florida
Scri Florida Cancer Specialists North
St. Petersburg, Florida
Augusta University
Augusta, Georgia
Norton Cancer Institute Pavilion
Louisville, Kentucky
Dana Farber Cancer Institute
Boston, Massachusetts
Forrest General Hospital Cancer Center
Hattiesburg, Mississippi
Scri Hca Midwest Health
Kansas City, Missouri
Nebraska Medical Center
Omaha, Nebraska
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Atlantic Health System
Morristown, New Jersey
Morristown Medical Center
Morristown, New Jersey
Columbia University Medical Center
New York, New York
Clinical Research Alliance, Inc
Westbury, New York
Duke University Hospital
Durham, North Carolina
Oregon Health and Science University
Portland, Oregon
Willamette Valley Cancer Center
Springfield, Oregon
Scri Tennessee Oncology Chattanooga
Chattanooga, Tennessee
Sarah Cannon Cancer Center
Nashville, Tennessee
Texas Oncology Fort Worth Cancer Center
Fort Worth, Texas
The University of Texas Md Anderson Cancer Center
Houston, Texas
Joe Arrington Cancer Research and Treatment Center
Lubbock, Texas
Texas Oncology San Antonio Medical Center Usor
San Antonio, Texas
Texas Oncology Tyler Longview
Tyler, Texas
Blue Ridge Cancer Care (Oncology and Hematology Associates of Southwest Virginia)
Roanoke, Virginia
Va Puget Sound Health Care System
Seattle, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington
Medical Oncology Associates
Spokane, Washington
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Princess Alexandra Hospital
Brisbane, Queensland, Australia
Icon Cancer Foundation
South Brisbane, Queensland, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Monash Health
Clayton, Victoria, Australia
Peninsula Private Hospital
Frankston, Victoria, Australia
Royal Perth Hospital
Perth, Western Australia, Australia
Gasthuiszusters Antwerpen Sint Augustinus
Wilrijk, Belgium
Peking University Third Hospital
Beijing, Beijing Municipality, China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.